Nautilus Historical Financial Ratios
| NAUT Stock | USD 1.92 0.09 4.48% |
Nautilus Biotechnology is lately reporting on over 90 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Nautilus Biotechnology financial condition quickly.
Nautilus |
About Nautilus Financial Ratios Analysis
Nautilus BiotechnologyFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Nautilus Biotechnology investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Nautilus financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Nautilus Biotechnology history.
Nautilus Biotechnology Financial Ratios Chart
Add Fundamental
Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Capex To Depreciation
The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.Most ratios from Nautilus Biotechnology's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Nautilus Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nautilus Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Nautilus Stock please use our How to Invest in Nautilus Biotechnology guide.At this time, Nautilus Biotechnology's PTB Ratio is comparatively stable compared to the past year. Capex To Depreciation is likely to gain to 0.88 in 2025, whereas Operating Cash Flow Per Share is likely to drop (0.39) in 2025.
Nautilus Biotechnology fundamentals Correlations
Click cells to compare fundamentals
Nautilus Biotechnology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Nautilus Biotechnology fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Ptb Ratio | (10.94) | 1.2 | 0.71 | 1.41 | 1.62 | 2.12 | |
| Book Value Per Share | (0.99) | 4.3 | 2.53 | 2.12 | 1.91 | 1.49 | |
| Operating Cash Flow Per Share | (1.34) | (0.47) | (0.46) | (0.37) | (0.41) | (0.39) | |
| Capex To Depreciation | 0.39 | 0.8 | 0.68 | 0.43 | 0.49 | 0.88 | |
| Pb Ratio | (10.94) | 1.2 | 0.71 | 1.41 | 1.62 | 2.12 | |
| Free Cash Flow Per Share | (1.47) | (0.5) | (0.49) | (0.39) | (0.43) | (0.41) | |
| Roic | (0.21) | (0.13) | (0.2) | (0.25) | (0.29) | (0.28) | |
| Net Income Per Share | (0.001338) | (0.52) | (0.6) | (0.51) | (0.59) | (0.56) | |
| Cash Per Share | 2.56 | 4.09 | 1.48 | 1.39 | 1.6 | 1.52 | |
| Pocfratio | (23.23) | (11.15) | (4.9) | (7.22) | (8.31) | (8.72) | |
| Capex To Operating Cash Flow | (0.0658) | (0.0578) | (0.0507) | (0.0472) | (0.0425) | (0.0446) | |
| Pfcf Ratio | (21.79) | (10.54) | (4.66) | (6.9) | (7.93) | (8.33) | |
| Income Quality | 0.9 | 0.78 | 0.79 | 0.81 | 0.73 | 0.52 | |
| Roe | 0.53 | (0.14) | (0.2) | (0.24) | (0.28) | (0.26) | |
| Ev To Operating Cash Flow | (20.95) | (7.18) | (3.06) | (7.52) | (6.77) | (7.1) | |
| Pe Ratio | (20.81) | (8.7) | (3.52) | (5.87) | (5.28) | (5.54) | |
| Return On Tangible Assets | (5.19E-4) | (0.18) | (0.13) | (0.21) | (0.24) | (0.23) | |
| Ev To Free Cash Flow | (19.66) | (6.79) | (2.91) | (7.18) | (6.46) | (6.78) | |
| Earnings Yield | (0.048) | (0.12) | (0.28) | (0.17) | (0.2) | (0.19) | |
| Net Debt To E B I T D A | 2.4 | 3.28 | 1.54 | (0.2) | (0.18) | (0.19) | |
| Current Ratio | 25.73 | 60.09 | 27.57 | 19.39 | 22.29 | 21.18 | |
| Tangible Book Value Per Share | (0.99) | 4.3 | 2.53 | 2.12 | 1.91 | 1.49 | |
| Graham Number | 3.41 | 7.6 | 5.39 | 4.94 | 5.68 | 10.74 | |
| Shareholders Equity Per Share | (0.99) | 4.3 | 2.53 | 2.12 | 1.91 | 1.49 | |
| Debt To Equity | (0.16) | 0.0826 | 0.0963 | 0.13 | 0.15 | 0.14 | |
| Capex Per Share | 0.0307 | 0.0269 | 0.0187 | 0.0195 | 0.0225 | 0.0214 | |
| Graham Net Net | (1.27) | 3.68 | 1.2 | 1.07 | 1.23 | 1.16 | |
| Interest Debt Per Share | 0.16 | 0.36 | 0.29 | 0.28 | 0.32 | 0.3 | |
| Debt To Assets | 0.0562 | 0.0754 | 0.0866 | 0.11 | 0.13 | 0.12 | |
| Enterprise Value Over E B I T D A | (22.09) | (5.94) | (2.57) | (5.23) | (4.71) | (4.94) | |
| Price Earnings Ratio | (20.81) | (8.7) | (3.52) | (5.87) | (5.28) | (5.54) | |
| Price Book Value Ratio | (10.94) | 1.2 | 0.71 | 1.41 | 1.62 | 2.12 | |
| Price To Operating Cash Flows Ratio | (23.23) | (11.15) | (4.9) | (7.22) | (8.31) | (8.72) | |
| Price To Free Cash Flows Ratio | (21.79) | (10.54) | (4.66) | (6.9) | (7.93) | (8.33) | |
| Ebt Per Ebit | 0.99 | 1.0 | 0.91 | 0.84 | 0.75 | 0.79 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nautilus Stock Analysis
When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.